Lenalidomide, an antiproliferative CLL drug

Abstract

In this issue of Blood, Fecteau et al show that lenalidomide inhibits proliferation of chronic lymphocytic leukemia (CLL) cells in vitro by targeting cereblon. Thus far, the clinical activity of this drug in CLL was believed to be mainly via the microenvironment.